240 related articles for article (PubMed ID: 27776453)
21. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.
Christensen M; Knop FK; Holst JJ; Vilsboll T
IDrugs; 2009 Aug; 12(8):503-13. PubMed ID: 19629885
[TBL] [Abstract][Full Text] [Related]
22. An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review.
Okere AN; Montesdeoca J; Glasper A; Diaby V
Curr Diabetes Rev; 2018; 14(4):363-375. PubMed ID: 28738763
[TBL] [Abstract][Full Text] [Related]
23. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
Darmon P; Raccah D
Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.
Cimmaruta D; Maiorino MI; Scavone C; Sportiello L; Rossi F; Giugliano D; Esposito K; Capuano A
Expert Opin Drug Saf; 2016 Dec; 15(sup2):77-83. PubMed ID: 27875915
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes.
Werner U; Haschke G; Herling AW; Kramer W
Regul Pept; 2010 Sep; 164(2-3):58-64. PubMed ID: 20570597
[TBL] [Abstract][Full Text] [Related]
26. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.
Goldenberg RM; Berard L
Curr Med Res Opin; 2018 Jan; 34(1):1-10. PubMed ID: 28836861
[TBL] [Abstract][Full Text] [Related]
27. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.
Tonneijck L; Muskiet MHA; Blijdorp CJ; Smits MM; Twisk JW; Kramer MHH; Danser AHJ; Diamant M; Joles JA; Hoorn EJ; van Raalte DH
Am J Physiol Renal Physiol; 2019 Feb; 316(2):F231-F240. PubMed ID: 30353743
[TBL] [Abstract][Full Text] [Related]
28. Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial.
Rayner CK; Watson LE; Phillips LK; Lange K; Bound MJ; Grivell J; Wu T; Jones KL; Horowitz M; Ferrannini E; Tricò D; Frascerra S; Mari A; Natali A
Diabetes Care; 2020 Aug; 43(8):1813-1821. PubMed ID: 32471908
[TBL] [Abstract][Full Text] [Related]
29. A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents.
Cornell S
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):17-27. PubMed ID: 32910490
[TBL] [Abstract][Full Text] [Related]
30. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.
Goldman J; Trujillo JM
Ann Pharmacother; 2017 Nov; 51(11):990-999. PubMed ID: 28645216
[TBL] [Abstract][Full Text] [Related]
31. Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance.
Whyte MB; Shojaee-Moradie F; Sharaf SE; Jackson NC; Fielding B; Hovorka R; Mendis J; Russell-Jones D; Umpleby AM
J Clin Endocrinol Metab; 2019 Feb; 104(2):359-368. PubMed ID: 30215735
[TBL] [Abstract][Full Text] [Related]
32. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
Fernández-García JC; Colomo N; Tinahones FJ
Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
[TBL] [Abstract][Full Text] [Related]
33. Novel GLP-1 receptor agonists for diabetes.
Garber AJ
Expert Opin Investig Drugs; 2012 Jan; 21(1):45-57. PubMed ID: 22111970
[TBL] [Abstract][Full Text] [Related]
34. Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option.
Gómez-Huelgas R; Azriel S; Puig-Domingo M; Vidal J; de Pablos-Velasco P
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):230-40. PubMed ID: 25066229
[TBL] [Abstract][Full Text] [Related]
35. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
36. An overview of new GLP-1 receptor agonists for type 2 diabetes.
Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
Expert Opin Investig Drugs; 2016; 25(2):145-58. PubMed ID: 26587691
[TBL] [Abstract][Full Text] [Related]
37. Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes.
Blonde L; Anderson JE; Chava P; Dendy JA
Curr Med Res Opin; 2019 May; 35(5):793-804. PubMed ID: 30370783
[TBL] [Abstract][Full Text] [Related]
38. Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients.
Tonneijck L; Muskiet MHA; Twisk JW; Kramer MHH; Danser AHJ; Joles JA; Smits MM; van Raalte DH
Hypertension; 2018 Aug; 72(2):314-322. PubMed ID: 29915021
[TBL] [Abstract][Full Text] [Related]
39. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia.
Lu JM
Adv Ther; 2019 Apr; 36(4):798-805. PubMed ID: 30859500
[TBL] [Abstract][Full Text] [Related]
40. [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?].
Nauck M; Wilhelm B
MMW Fortschr Med; 2017 Jun; 159(Suppl 5):7-15. PubMed ID: 28643293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
